'Palliative-D' Vitamin D to Palliative Cancer Patients

• Status: Completed
• Trial end date: 2020-06-09
• Target enrollment: 0
• Participant gender: All

Summary

To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients can decrease opioid consumption, fatigue and infectious burden and increase quality of life.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Region Stockholm; Stockholm County Council, Sweden
• Treatments: Cholecalciferol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

1. Patients admitted to ASIH Stockholm Södra or Stockholms Sjukhem.

2. Incurable cancer patients with any type of cancer. They could have ongoing oncological treatment but only with palliative intention. No patients with ongoing oncological treatment with curative intended treated will be included.

3. The life expectancy should be at least 3 months according to the clinical assessment of the study physician at the screening visit.

4. The patient should have no cognitive failure, being able to comprehend oral and written information about the study.

5. 25 OHD < 50 nmol/L.

6. Men and women aged ≥18

7. Signed 'informed consent'

Exclusion Criteria:

1. Ongoing vitamin D supplementation at the time for inclusion.

2. Serum level of 25-OH vitamin D3 >50 nmol/L

3. Known sarkoidosis

4. Treatment with tiazides or digoxin or digitoxin

5. Primary hyperparathyroidism

6. Hypercalcaemia (verified by a laboratory result younger than 2 month)

7. Plans to leave the Stockholm county within 12 weeks of inclusion

8. History of kidney stones

9. Taking part of another clinical study involving drugs

10. Hypersensitivity to cholecalciferol and/or any of the excipients

11. Other criteria that could jeopardize the study or its intention as judged by the investigator

12. Not being able to perform EORTC-QLQ-C15-PAL or ESAS